![]() |
Home
Search
Study Topics
Glossary
|
Study 15 of 3601 for search of: | United States, Virginia |
![]() |
Previous Study | Return to Search Results | Next Study |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00002611 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer.
PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
Condition | Intervention | Phase |
---|---|---|
Kidney Cancer |
Drug: cyclophosphamide Drug: dactinomycin Drug: doxorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: vincristine sulfate Procedure: conventional surgery Procedure: radiation therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY |
Ages Eligible for Study: | up to 15 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed stage I-V kidney cancer of one of the following histologies:
Rhabdoid tumor
Prior nephrectomy or biopsy required
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Study Chair: | Daniel M. Green, MD | Roswell Park Cancer Institute |
Study ID Numbers: | CDR0000063901, COG-Q9401, NWTS-Q9401, CCG-4941, POG-9440, INT-0150, NWTS-5 |
Study First Received: | November 1, 1999 |
Last Updated: | November 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00002611 |
Health Authority: | United States: Federal Government |
stage I Wilms tumor stage II Wilms tumor stage III Wilms tumor |
stage IV Wilms tumor stage V Wilms tumor clear cell sarcoma of the kidney |
Malignant mesenchymal tumor Wilms' tumor Vincristine Sarcoma, Clear Cell Urogenital Neoplasms Cyclophosphamide Renal cancer Kidney cancer Urologic Neoplasms Etoposide phosphate Doxorubicin Soft tissue sarcomas |
Carcinoma Urologic Diseases Dactinomycin Kidney Neoplasms Sarcoma Carcinoma, Renal Cell Wilms Tumor Kidney Diseases Adenocarcinoma Etoposide Urinary tract neoplasm Neoplasms, Glandular and Epithelial |
Anti-Infective Agents Neoplasms by Histologic Type Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Mitosis Modulators Physiological Effects of Drugs Enzyme Inhibitors Antimitotic Agents Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |
Protein Synthesis Inhibitors Anti-Bacterial Agents Neoplasms Neoplasms by Site Therapeutic Uses Tubulin Modulators Myeloablative Agonists Antineoplastic Agents, Alkylating Antirheumatic Agents Antineoplastic Agents, Phytogenic Alkylating Agents Nucleic Acid Synthesis Inhibitors |